AIM ImmunoTech (AIM) News Today $0.09 -0.03 (-22.34%) As of 04/4/2025 This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AIM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®June 12 at 8:30 AM | globenewswire.comAIM ImmunoTech Announces NYSE American Removal of Trading SuspensionJune 12 at 8:00 AM | globenewswire.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces 1-for-100 Reverse Stock SplitJune 12 at 7:05 AM | finanznachrichten.deAIM ImmunoTech Announces 1-for-100 Reverse Stock SplitJune 11 at 4:15 PM | globenewswire.comAIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of ImmunologistsMay 8, 2025 | globenewswire.comAIM ImmunoTech Inc AIMIApril 19, 2025 | morningstar.comAIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open MarketApril 7, 2025 | globenewswire.comAIM ImmunoTech Inc trading halted, news pendingApril 5, 2025 | markets.businessinsider.comNYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)April 4, 2025 | businesswire.comAIM ImmunoTech Announces NYSE American Notice of Delisting and AppealApril 4, 2025 | globenewswire.comAIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call TranscriptApril 3, 2025 | msn.comQ4 2024 AIM ImmunoTech Inc Earnings CallApril 2, 2025 | finance.yahoo.comAIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comAIM ImmunoTech made ‘significant strides’ over course of 2024March 27, 2025 | markets.businessinsider.comEarnings Preview For AIM ImmunoTechMarch 27, 2025 | benzinga.comAIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 27, 2025 | markets.businessinsider.comAIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceMarch 11, 2025 | globenewswire.comInsider Buying: AIM ImmunoTech Inc. (NYSE:AIM) CEO Acquires 83,334 Shares of StockMarch 5, 2025 | insidertrades.comAIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenzaFebruary 28, 2025 | globenewswire.comAIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing ComplianceFebruary 26, 2025 | globenewswire.comAIM ImmunoTech appoints Chemerow as an Independent DirectorFebruary 26, 2025 | msn.comAIM ImmunoTech Appoints David Chemerow to BoardFebruary 26, 2025 | tipranks.comAIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent DirectorFebruary 26, 2025 | globenewswire.comAIM ImmunoTech doses first subject in Phase 2 study of Ampligen, ImfinziFebruary 26, 2025 | markets.businessinsider.comAIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic CancerFebruary 25, 2025 | globenewswire.comAIM stock touches 52-week low at $0.13 amid market challengesFebruary 14, 2025 | msn.comAIM ImmunoTech to not proceed with offering pursuant to registration statementFebruary 11, 2025 | markets.businessinsider.comAIM ImmunoTech Releases Virtual Investor “What This Means Segment”February 11, 2025 | globenewswire.comAIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024February 11, 2025 | globenewswire.comAIM ImmunoTech announces follow-up clinical study of Ampligen with FluMistFebruary 8, 2025 | markets.businessinsider.comAIM ImmunoTech advances Ampligen for avian influenza vaccineFebruary 8, 2025 | msn.comAIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaksFebruary 7, 2025 | globenewswire.comAIM ImmunoTech announces Safety Committee approval to proceed with Phase 2February 5, 2025 | markets.businessinsider.comCornish Metals Inc ("Cornish Metals" or the "Company") (AIM/TSX-V: CUSN) Result of Retail OfferJanuary 31, 2025 | globenewswire.comCornish Metals Inc (AIM/TSX-V: CUSN) ("Cornish Metals" or the "Company") Result of FundraisingJanuary 28, 2025 | globenewswire.comAIM ImmunoTech files to sell units, no amount givenJanuary 23, 2025 | msn.comAIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID ConditionsJanuary 23, 2025 | globenewswire.comAIM ImmunoTech highlights new article on links between COVID-19, ME/CFSJanuary 22, 2025 | markets.businessinsider.comAIM ImmunoTech Highlights Higher Post-COVID Prevalence Of Myalgic Encephalomyelitis/Chronic FatigueJanuary 22, 2025 | markets.businessinsider.comAIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFSJanuary 22, 2025 | globenewswire.comAIM ImmunoTech highlights 2024 milestones achievedJanuary 16, 2025 | markets.businessinsider.comAIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving MilestonesJanuary 15, 2025 | globenewswire.comTed Kellner low-key on joining pharma firm board he fought to joinDecember 20, 2024 | bizjournals.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsDecember 18, 2024 | finanznachrichten.deAIM ImmunoTech receives noncompliance notification from NYSEDecember 18, 2024 | markets.businessinsider.comPharma company proxy fight ends in mixed results for Ted KellnerDecember 17, 2024 | bizjournals.comAIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsDecember 17, 2024 | globenewswire.comAIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual MeetingDecember 17, 2024 | businesswire.comTed Kellner's multimillion-dollar fight to unseat pharma firm's boardDecember 17, 2024 | bizjournals.comAIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy CardDecember 16, 2024 | tmcnet.com Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address AIM Media Mentions By Week AIM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AIM News Sentiment▼0.000.87▲Average Medical News Sentiment AIM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AIM Articles This Week▼22▲AIM Articles Average Week Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IPA News EGRX News GBIO News CYCC News TENX News NNVC News TPST News CARA News CALC News CYTH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AIM) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AIM Stock Free AIM Stock Alerts